Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jun 3, 2026
- Accession no.
- 0001193125-26-256013
- Filed
- Jun 3, 2026
- Trade date
- Jun 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.76M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseAcquired | +25,000 | $8.27 | +$206,750 | 33,977 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −21,069 | $70.11F3 | −$1,477,147.59 | 12,908 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −3,931 | $70.75F4 | −$278,118.25 | 8,977 | Direct | |
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +615 | $70.44F6 | +$43,320.6 | 9,592 | Direct | |
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +615 | $0.00 | $0 | 10,207 | Direct | |
| Jun 2, 2026 | Common Stock | FTax withholdingDisposed | −452 | $70.44F9 | −$31,838.88 | 9,755 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 141,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.49 to $70.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.49 to $70.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F6
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F9
The closing price on June 1, 2026 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.